All In Biotech

Drug Trial Radar · NCT06905054

Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation

Peroxisome Proliferator-Activated Receptor Agonists to Prevent Primary Sclerosing Cholangitis Recurrence After Liver Transplantation

Last checked: Nov 20, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Apr 15, 2025

Primary completion

Mar 30, 2028

Study completion Jul 1, 2028

Sponsor

Lead sponsor
Mayo ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to determine the efficacy of 36 months once-daily fenofibrate in preventing clinically-detectable recurrence of primary sclerosing cholangitis after liver transplantation, compared with a historical control cohort that was not treated with

Conditions

  • Primary Sclerosing Cholangitis
  • Liver Transplant, Complications
  • PSC
  • Biliary Strictures

Interventions

  • Fenofibrate (drug)Drug

    Once daily fenofibrate for 36 months

  • Blood draw for the laboratory assessmentDiagnostic test

    Serum assessments will be performed every 3 months during the study period

  • MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)Diagnostic test

    Participants will undergo a quantitative gadoxetate-enhanced MRI and MRCP at baseline, and at 12 months and 36 months of trial participation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the incidence of rPSC in LT recipients treated with fenofibrate, compared with an untreated control cohort.Time frame: 36 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic in Arizona

    Scottsdale, Arizona · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.